TITLE

Metabolic risk factor profile associated with use of second generation antipsychotics: a cross sectional study in a community mental health centre

AUTHOR(S)
Tarricone, Ilaria; Casoria, Michela; Gozzi, Beatrice Ferrari; Grieco, Daniela; Menchetti, Marco; Serretti, Alessandro; Ujkaj, Manjola; Pastorelli, Francesca; Berardi, Domenico
PUB. DATE
January 2006
SOURCE
BMC Psychiatry;2006, Vol. 6, p11
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Second generation antipsychotics (SGA) have demonstrated several advantages over first generation antipsychotics (FGA) in terms of positive, negative, cognitive, and affective symptoms and a lower propensity for extrapyramidal side effects. Despite these undeniable advantages, SGA have been associated with causing and exacerbating metabolic disorders, such as obesity, diabetes, and hyperlipidemia. This cross sectional study aimed to evaluate the metabolic risk factor profile associated with use of SGAs in comparison with non-treated control patients. Methods: The study was carried out at a Community Mental Health Centre (CMHC) in Bologna. The study subjects were outpatients with serious mental disorders treated with SGA (clozapine, olanzapine, risperidone, quetiapine). A sample of adult men and women suffering from idiopathic hyperhydrosis, without psychiatric history or antipsychotic treatment, were randomly selected from outpatients of the Department of Neurology in Bologna as a reference group. We investigated differences among the treatment and reference groups for glycaemia, cholesterolaemia and triglyceridaemia levels. Results: The study sample was composed of 76 patients, 38 males and 38 females. The reference group was composed of 36 subjects, 19 females and 17 males. All patients treated with SGAs had higher mean glycaemia and triglyceridaemia and a significantly higher risk of receiving a diagnosis of hyperglycaemia and hypertriglyceridaemia than the reference group. We did not find any differences in mean glycaemia or mean triglyceridaemia levels among treatment groups. Patients with clozapine had a significantly higher mean BMI value and rate of obesity than patients treated with other SGAs. Conclusion: The rate of obesity and metabolic disorders observed in this study were higher than the prevalence in the control group and similar to that previously reported in psychiatric samples; these findings imply per se that more attention should be paid to the metabolic condition of psychiatric patients. In line with the International Consensus Conferences we recommend that monitoring of weight, fasting plasma glucose, cholesterol and triglyceride levels be obtained in routine clinical practice with all antipsychotics.
ACCESSION #
29323739

 

Related Articles

  • Possible Link Explored Between Antipsychotics And Several Conditions.  // RN;Jun2004, Vol. 67 Issue 6, p76 

    Explores the possible link between antipsychotics and several conditions. Recommendation for monitoring closely on patients who take antipsychotics for signs that they are developing diabetes, obesity, or high cholesterol; Emergence of the consensus statement made by the American Diabetes...

  • Weight Gain, Obesity, and Psychotropic Prescribing. Nihalani, Nikhil; Schwartz, Thomas L.; Siddiqui, Umar A.; Megna, James L. // Journal of Obesity;2011, Vol. 2011, Special section p1 

    A majority of psychiatric medications are known to generate weight gain and ultimately obesity in some patients. There is much speculation about the prevalence of weight gain and the degree of weight gain during acute and longitudinal treatment with these agents. There is newer literature...

  • Zneužívání psychoaktivních látek a diabetes mellitus. Nešpor, K.; Vincent, L. // General Practitioner / Prakticky Lekar;Jan2012, Vol. 92 Issue 1, p50 

    Abuse of psychoactive substances, particularly in diabetic patients means risk from biological and psychosocial reasons. Number of diabetics in the Czech Republic in 2010 was around 800 000 people. In addition, Czech belongs to the countries with the highest alcohol consumption in the world and...

  • A Relationship Between Antidepressants and Diabetes. Kuritzky, Louis // Internal Medicine Alert;4/29/2008, Vol. 30 Issue 8, p64 

    The article discusses a study which examines the relationship between antidepressant medications and diabetes. The risk of progressing to diabetes were not associated with depression but was associated with use of antidepressants. In addition, since antidepressant use has been associated with...

  • Chapter Ten: HEALTH AND SAFETY CONSIDERATIONS. Austin, Joan K.; Dunn, David W.; Price, Martha J. // Therapeutic Recreation (5th ed.);2004, p453 

    Presents health and safety information to be considered when providing services for recreational therapy clients who have a seizure disorder, who are receiving medication for diabetes mellitus, or who are being treated with psychotropic drugs. Safety precautions when working with persons with...

  • Clinical: Journals Watch - Obesity, cancer pain and exercise. Jacobi, Tillmann // GP: General Practitioner;4/15/2011, p33 

    The article presents recent updates related to recent research works done in the field of medicine. One research in the "New England Journal of Medicine" states that obesity exacerbates age-related decline in physical function in older adults. Another study in the "International Journal of...

  • A behavioral weight-loss intervention for persons with serious mental illness in psychiatric rehabilitation centers. Daumit, G. L.; Dalcin, A. T.; Jerome, G. J.; Young, D. R.; Charleston, J.; Crum, R. M.; Anthony, C.; Hayes, J. H.; McCarron, P. B.; Khaykin, E.; Appel, L. J. // International Journal of Obesity;Aug2011, Vol. 35 Issue 8, p1114 

    Objective:Overweight and obesity are epidemic in populations with serious mental illnesses. We developed and pilot-tested a behavioral weight-loss intervention appropriately tailored for persons with serious mental disorders.Methods:We conducted a single-arm pilot study in two psychiatric...

  • Psychotropic Drugs in the Treatment of Obesity: What Promise? Appolinario, Jose C.; Bueno, João R.; Coutinho, Walmir // CNS Drugs;2004, Vol. 18 Issue 10, p629 

    Obesity is a chronic and highly prevalent medical condition associated with increased risk for the development of numerous and sometimes fatal diseases. Despite its severity, there are few anti-obesity agents available on the market. Although psychotropic agents are not approved for the...

  • The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats. Fell, M. J.; Anjum, N.; Dickinson, K.; Marshall, K. M.; Peltola, L. M.; Vickers, S.; Cheetham, S.; Neill, J. C. // Psychopharmacology;Oct2007, Vol. 194 Issue 2, p221 

    Treatment with some antipsychotic drugs may result in excessive body weight gain which can have detrimental effects on patient compliance, morbidity and mortality. The aim of the present study was to investigate the effect of atypical antipsychotic drugs on dietary macronutrient selection, body...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics